jili casino sites
NoneUnai Emery feels confidence returning after Aston Villa end winless run
New Orleans Police say 3 shot, 1 killed in French QuarterThe trade group of Colorado hospitals is preparing for a political battle at the state Capitol to maintain a federal drug discount program that the group says benefits nearly 70 hospitals statewide. Critics of the program known as 340B argue it has been widely abused and misused, particularly by large hospitals. While it is a federal program, Julie Lonborg, senior vice president of Colorado Hospital Association, said her group will turn to the Colorado state legislature next year to push legislation to protect hospitals from losing funding. The program, she said, is under attack by the pharmaceutical industry. The group and officials from several hospitals hosted a virtual roundtable on Dec. 10 to discuss maintaining funding they argued is needed to keep hospitals on track. In the meeting organized by the trade group, Lonborg said 68 of the state’s 88 hospitals qualify for the 340B program. The federal 340B Drug Pricing Program, established in 1992 as part of the Public Health Service Act, allows eligible healthcare organizations to purchase outpatient drugs at a discount from manufacturers. In an email to Colorado Politics, Cara Welch, the group's communications director, said protecting 340B is a priority. No legislation has been drafted yet and no sponsors at the Capitol have been found, Welch said. Welch said that, since 2020, pharmacies have started limiting hospitals' participation in the program, adding that states have oversight, though 340B is a federal program. Last month, a three-member panel attended a healthcare forum in Denver said large hospitals are abusing the program that is supposed to help pay healthcare costs for low-income families. The panel said fixing the program cannot happen at the state level, maintaining Congress must fix it. During the Nov. 12 forum, William Smith, a senior fellow at the Pioneer Institute, said pharmacy benefit managers (PBMs) and large hospitals have learned how to profit from the program. For example, a cancer drug costing around $200,000 is only $25,000 for hospitals with 340B status. However, the hospital is still billing insurance companies for $200,000 and “pocketing $175,000 in profits," he said. “That's really what's driving this program — is the ability of hospitals to arbitrage the discounts,” Smith said. “And what's happened is hospitals have gone out into wealthy neighborhoods and have purchased physician practices, particularly physician practices that prescribe high-cost drugs, like rheumatologists or oncologists, and they bought them up so that they could charge more to the discounts for profit.” Critics also said the program has become mismanaged and underregulated due to staff shortages at the Health Resources and Services Administration, which oversees it. Others said hospitals have not been transparent about using 340B funding. Courtney Christian, deputy vice chair of policy and research for PhRMA, said the solution is not be to eliminate the 340B program because it has value to hospitals when applied correctly, noting that its primary purpose is to help patients in need and support charitable programs. The hospital association said keeping the program is vital. The main question is whether state lawmakers would make changes or leave the issue completely up to the federal government. “The powerful pharmaceutical industry has mounted a coordinated national effort to weaken 340B, even though this discount program accounts for 3% of the drug companies’ profits globally," the association said. "Despite the minimal impact to pharmaceutical companies, 340B is an essential lifeline for 68 participating Colorado hospitals with; 89% of which operate with low or negative margins.” Meanwhile, Kevin Forbush, the 340B program director at Intermountain Health in Brighton, said he disagrees with the assertion that the program does not have oversight, noting he has taken part in audits for the last 10 years. “This is a highly regulated program that’s administered by the federal government, Forbush said. “I, myself have been through six of these audits. They are very intense.” Forbush described a system where hospitals must undergo a process to meet stringent criteria. Under the 340B program, a patient who needs blood thinner medication pays 28 cents when the regular cost is $500; hence, the 340B program, which aims to bring down drug costs, works, he said. Chris Thomas, the president and CEO of Community Hospital in Grand Junction, said hospitals are already operating on thin margins, and “340B funding for us is absolutely critical.” For some hospitals barely operating in the black, hospital officials say losing funding could force them to operate at a deficit. UCHealth Vice President Dan Weaver said that UCHealth is the state’s largest MedCaid provider and that it continues to see the number of uninsured patients grow. “340B is extremely important to us,” he said. “Not only do some of the of our hospitals qualify for 340B because of the amount of uncompensated care that they provide, but 340B makes that uncompensated care possible.” Being in an urban community, Thomas said the Community Hospital is five miles from another hospital and considered too big to be a critical access facility. With 340B funding, Thomas said, the hospital has invested in a better OB and midwife program. “We embed our midwives,” he said. “They go into our safety net clinic on a weekly basis and see patients on a sliding scale. We know that giving prenatal care early and often saves money, saves lives and improves the health of our community.” At the November forum, Jonathan Campbell, the chief science officer for the National Pharmaceutical Council, said those who are abusing the 340B program are costing the healthcare industry an estimated $5 billion.
AP Trending SummaryBrief at 7:10 a.m. ESTBy Leah Nylen and Jaewon Kang | Bloomberg A judge blocked Kroger Co.’s $24.6 billion acquisition of Albertsons Cos. , finding the takeover would lessen competition for US grocery shoppers, in a ruling that marks a likely death knell for the deal. In a decision filed in Oregon federal court Tuesday, US District Judge Adrienne Nelson found in favor of the US Federal Trade Commission. The agency had argued that the proposed tie-up violates US antitrust law and that a division of hundreds of stores to C&S Wholesale Grocers Inc. wouldn’t do enough to replace the lost competition. Also see: Biggest question from Kroger-Albertsons trial: What’s a grocery store? “There is ample evidence that the division is not sufficient in scale to adequately compete with the merged firm and is structured in a way that will significantly disadvantage C&S as a competitor,” Nelson wrote. “The deficiencies in the disvestiture scope and structure create a risk that some or all of the divested stores will lose sales or close, as has happened in past C&S acquisitions.” Nelson’s decision is a major victory for the FTC and its outgoing Chair Lina Khan, who came under harsh criticism from conservatives and business groups for stepped-up antitrust enforcement under the Biden administration. “Today’s win protects competition in the grocery market, which will prevent prices from rising even more,” said FTC spokesperson Douglas Farrar. “This statement makes it clear that strong, reality-based antitrust enforcement delivers real results for consumers, workers, and small businesses.” Also see: Albertsons would have shed these 63 California stores A C&S Wholesale spokesperson said the company is disappointed by the court’s decision and that it looks forward to seeing how Kroger and Albertsons will determine the next steps of the proposed deal. Kroger and Albertsons didn’t immediately respond to requests for comment. Attorneys for the companies have said the acquisition would probably be called off if the judge ruled against the deal. Kroger shares jumped as much as 6.1% in New York trading on Tuesday, extending earlier gains. Albertsons slumped as much as 10%. Specific Market Nelson agreed with the FTC that supermarkets constitute a specific market, countering the companies’ argument that the market extends to online retailers like Amazon.com Inc. “Supermarkets are distinct from other grocery retailers,” Nelson wrote. “Supermarkets offer a larger selection of fresh and non-perishable items, a one-stop shopping experience that appeals to a particular consumer’s preference to meet all their grocery needs in one location, and a customer service focus with deli, bakery, meat, and other specialized departments.” The ruling marks a disappointing end to a two-year odyssey by Kroger and Albertsons, which sought to become a bigger player with a more substantial national footprint to better compete against larger, non-unionized rivals including Walmart Inc. Kroger and Albertsons agreed to combine in October 2022 in what would have been the biggest US grocery deal in history, bringing together more than 4,000 stores across 48 states and Washington, DC. Kroger will likely turn its focus back to improving and investing in its existing network of about 2,750 stores. Albertsons, on the other hand, could emerge again as a deal target, but is expected in the near term to invest in its roughly 2,270 stores and technology. The proposed deal has been a political hot potato, drawing pushback from elected officials, union groups and consumer advocacy firms. The companies vowed to spend $1 billion to cut prices, $1.3 billion to improve store conditions and $1 billion to raise worker wages and benefits following the deal. The FTC has increased antitrust enforcement under the Biden administration, though the results in court have been mixed. The FTC lost a challenge to Microsoft Corp.’s acquisition of Activision Blizzard Inc. and won against Illumina Inc. over its purchase of startup Grail and against Tapestry Inc.’s planned $8.5 billion acquisition of Capri Holdings Inc. The companies and the agency fought their case in court for three weeks over the summer in Oregon, as grocery inflation came back into the political spotlight ahead of the US presidential election. Grocery inflation hit a four-decade high in 2022 due to higher costs of labor, transportation and ingredients. Price increases have moderated and are expected to stay within historical ranges, though many American shoppers still say expensive groceries continue to squeeze their ability to spend. The FTC argued that the deal would harm consumers by eliminating competition on prices and quality, making the combined entity less likely to improve its services by offering flexible hours and pickup services. It said the grocers would have more leverage over workers, which would slow wage growth and worsen benefits, and that the proposed divestiture would be inadequate. The agency tried to depict Kroger and Albertsons as the most direct competitors. It said the deal would combine the two largest “traditional supermarkets” in a market that includes Walmart and Target, but does not include Amazon, Costco, Aldi and dollar stores. The companies argued that such a definition is “antiquated” and no longer describes how people shop and pointed to various changes they have made in response to newer threats. The grocers also said joining forces would help them increase market share and improve technology to compete with Amazon, Walmart and other companies. The case is Federal Trade Commission v. Kroger Co., 24-cv-00347, US District Court, District of Oregon (Portland). Related Articles Retail | Fear of Trump tariffs sending Americans into debt as pantry stockpiling rises Retail | Costco’s popular Kirkland diapers shifting suppliers Retail | Cyber Monday shoppers expected to set a record on the year’s biggest day for online shopping Retail | SunFed cucumbers and Costco eggs recalled due to potential salmonella contamination Retail | Gifting on a budget: 5 secrets to being generous without going brokeGet free Frostys for the entire year with $3 Wendy's Key Tag
‘The smiling one’ Ruben Amorim says he can be ruthless when he needs to be
Women more likely to need walking aids but less likely to use them – studyBill Ackman is a billionaire nine times over, according to Forbes . He made his vast wealth by running Pershing Square Capital, the hedge fund he founded 20 years ago. He increased his fame (and made a lot of money) during the financial crisis by betting against bond insurer MBIA and rescuing mall operator General Growth Properties. Ackman has a concentrated investment style. His fund typically has 10 holdings or less, and when he finds something he likes, he bets big on it. One stock he recently loaded up on is Brookfield (NYSE: BN) -- which also happens to be one of my favorite stocks and top holdings. Here's why I think buying Brookfield was a wise move that will likely make Ackman even more money. Are You Missing The Morning Scoop? Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Betting big on Brookfield Ackman has been buying shares of Brookfield hand over fist. His stake in it has multiplied five-fold since June to 22 million shares. That position is currently worth over $1.7 billion, which is about 13% of his hedge fund's assets, making it the top holding. Brookfield isn't a household name among most investors, and the Canadian investment manager's operation might seem a bit complex at first glance. It has three core businesses: Asset management : The company owns a 73% interest in a leading alternative investment manager, and its Brookfield Asset Management business has over $1 trillion in assets under management . Wealth solutions : The company provides a variety of insurance products and services, including annuities, personal and commercial property and casualty insurance, and life insurance. Operating businesses : Brookfield has operating businesses in renewable power ( Brookfield Renewable ), infrastructure ( Brookfield Infrastructure ), business and industrial services ( Brookfield Business ), and real estate. In many ways, Brookfield is like a mix between Berkshire Hathaway and Blackstone . Similar to Berkshire, it has insurance operations and invests capital on behalf of investors into operating businesses (and its funds). Meanwhile, it also owns a large stake in a leading alternative asset manager that rivals Blackstone in size and expertise. Brookfield also has a strong leader, CEO Bruce Flatt, whom many have called the Warren Buffett of Canada. Like Buffett, Flatt is a value investor with a phenomenal track record of allocating capital to grow shareholder value. He's been with the company since 1990 and has been CEO since 2002. Over the last 20 years, Brookfield has delivered annualized total returns of 16%. That handily beat the S&P 500 and Berkshire Hathaway, both of which delivered annualized returns of about 11% during that period. What makes Brookfield such a smart investment right now Flatt believes Brookfield's best days lie ahead of it. Its long-term target is to deliver annualized returns of 15% or more over the long term. The company is in a better position than ever to achieve that. A few factors support that view. First, Brookfield believes the market is undervaluing the company today. Management estimates that the stock should trade at around $84 per share based on the earnings capacity of its core franchises. That's significantly above its current price of less than $60 per share. On top of that, Brookfield has significant embedded growth. The company expects to grow its earnings per share by more than 20% annually over the next five years. That forecast is based on the expected continued expansion of its asset management and wealth solutions businesses, the carried interest in its investment funds (its share of the profits), and its ability to adeptly allocate the excess capital generated by its operations. Brookfield expects to produce a cumulative $47 billion, or $30 per share, of free cash flow over the next five years, giving it plenty of cash to allocate toward growing shareholder value. The growth drives the company's belief that it will increase its underlying value to $176 per share by 2029 . That would amount to an annualized growth rate of 16% from its current estimated value and more than 25% from its actual share price. Ackman is right; Brookfield is a brilliant buy Brookfield and its subsidiaries are among my top holdings. I've held shares for more than a decade and routinely add to my position because Flatt is such a fantastic wealth creator. Like him, I believe Brookfield's best days are still ahead of it, which is why I think Ackman's decision to load up on shares is a brilliant move. I expect that decision will make him and his investors a lot of money. Don’t miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $380,291 !* Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,278 !* Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $484,003 !* Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon. See 3 “Double Down” stocks » *Stock Advisor returns as of November 18, 2024 Matt DiLallo has positions in Berkshire Hathaway, Blackstone, Brookfield Asset Management, Brookfield Corporation, Brookfield Infrastructure Corporation, Brookfield Infrastructure Partners, Brookfield Renewable, and Brookfield Renewable Partners and has the following options: short January 2025 $60 calls on Brookfield Corporation. The Motley Fool has positions in and recommends Berkshire Hathaway, Blackstone, Brookfield, Brookfield Asset Management, and Brookfield Corporation. The Motley Fool recommends Brookfield Infrastructure Partners, Brookfield Renewable, and Brookfield Renewable Partners. The Motley Fool has a disclosure policy . Billionaire Bill Ackman Recently Bought One of My Favorite Stocks. Here's Why I Think It Was a Brilliant Move. was originally published by The Motley Fool
Nigeria wants extradition of separatist arrested in Finland
Joe Burrow's home broken into during Monday Night Football in latest pro-athlete home invasionOfficer kills pet dog mistaken for a coyote in Massachusetts town. The owner says it was unnecessary An animal control officer shot and killed a pet dog in a Massachusetts town after mistaking it for a coyote in an incident local police are describing as a sad mix-up. Police in Northbridge, Massachusetts, say the shooting happened on Tuesday after police received a call of a report of a coyote in a residential backyard. Police say the animal control officer went into the woods to look for the coyote and found what they thought was the animal in a threatening position and shot it. The incident happened as communities around Massachusetts and the country have dealt with an uptick in interactions between coyotes and people. Alyssa Nakken, first full-time female coach in MLB history, leaving Giants to join Guardians CLEVELAND (AP) — Alyssa Nakken, the first woman to coach in an MLB game, is leaving the San Francisco Giants to join the Cleveland Guardians. Nakken made history in 2022 when she took over as first-base coach following an ejection. A former college softball star at Sacramento State, Nakken joined the Giants in 2014 and was promoted to a spot on manager Gabe Kapler’s staff in 2020, becoming the majors’ first full-time female coach. Nakken has been hired as an assistant director within player development for the Guardians, who won the AL Central last season under first-year manager Stephen Vogt. Nakken, 34, will work with former Giants coaches Craig Albernaz and Kai Correa. Kendrick Lamar surprises with new album 'GNX' LOS ANGELES (AP) — Kendrick Lamar gave music listeners an early holiday present with a new album. The Grammy winner released his sixth studio album “GNX” on Friday. The 12-track project is the rapper’s first release since 2022’s “Mr. Morale & The Big Steppers.” Lamar’s new album comes just months after his rap battle with Drake. The rap megastar will headline February's Apple Music Super Bowl Halftime Show in New Orleans. The 37-year-old has experienced massive success since his debut album “good kid, m.A.A.d city” in 2012. Since then, he’s accumulated 17 Grammy wins and became the first non-classical, non-jazz musician to win a Pulitzer Prize. NBA memo to players urges increased vigilance regarding home security following break-ins MIAMI (AP) — The NBA is urging its players to take additional precautions to secure their homes following reports of recent high-profile burglaries of dwellings owned by Milwaukee Bucks forward Bobby Portis and Kansas City Chiefs teammates Patrick Mahomes and Travis Kelce. In a memo sent to team officials, a copy of which was obtained by The Associated Press, the NBA revealed that the FBI has connected some burglaries to “transnational South American Theft Groups” that are “reportedly well-organized, sophisticated rings that incorporate advanced techniques and technologies, including pre-surveillance, drones, and signal jamming devices.” Ancient meets modern as a new subway in Greece showcases archaeological treasures THESSALONIKI, Greece (AP) — Thessaloniki, Greece’s second-largest city, is opening a new subway system, blending ancient archaeological treasures with modern transit technology like driverless trains and platform screen doors. The project, which began in 2003, uncovered over 300,000 artifacts, including a Roman-era thoroughfare and Byzantine relics, many of which are now displayed in its 13 stations. Despite delays caused by preserving these findings, the inaugural line has been completed, with a second line set to open next year. Conor McGregor must pay $250K to woman who says he raped her, civil jury rules LONDON (AP) — A civil jury in Ireland has awarded more than $250,000 to a woman who says she was raped by mixed martial arts fighter Conor McGregor in a Dublin hotel penthouse after a night of heavy partying. The jury on Friday awarded Nikita Hand in her lawsuit that claimed McGregor “brutally raped and battered” her in 2018. The lawsuit says the assault left her heavily bruised and suffering from post-traumatic stress disorder. McGregor testified that he never forced her to do anything and that Hand fabricated her allegations after the two had consensual sex. McGregor says he will appeal the verdict. At least 19 people are sick in Minnesota from ground beef tied to E. coli recall U.S. health officials say at least 19 people in Minnesota have been sickened by E. coli poisoning tied to a national recall of more than 167,000 pounds of potentially tainted ground beef. Detroit-based Wolverine Packing Co. recalled the meat sent to restaurants nationwide. Minnesota state agriculture officials reported multiple illnesses and found that a sample of the product tested positive for E. coli, which can cause life-threatening infections. No illnesses have been reported outside of Minnesota. Symptoms of E. coli poisoning include fever, vomiting, diarrhea and signs of dehydration. Actor Jonathan Majors’ ex-girlfriend drops assault and defamation lawsuit against once-rising star NEW YORK (AP) — Jonathan Majors’ ex-girlfriend has dropped her assault and defamation lawsuit against the once-rising Hollywood star after reaching a settlement. Lawyers for Majors and Grace Jabbari agreed to dismiss the case with prejudice Thursday. Jabbari is a British dancer who had accused Majors of subjecting her to escalating incidents of physical and verbal abuse during their relationship. Representatives for Majors didn’t respond to emails seeking comment Friday. Jabbari’s lawyer said the suit was “favorably settled” and her client is moving on with “her head held high.” Majors was convicted of misdemeanor assault and harassment last December and sentenced to a yearlong counseling program. Hyundai, Kia recall over 208,000 electric vehicles to fix problem that can cause loss of power DETROIT (AP) — Hyundai and Kia are recalling over 208,000 electric vehicles to fix a pesky problem that can cause loss of drive power, increasing the risk of a crash. The recalls cover more than 145,000 Hyundai and Genesis vehicles including the 2022 through 2024 Ioniq 5, the 2023 through 2025 Ioniq 6, GV60 and GV70, and the 2023 and 2024 G80. Also included are nearly 63,000 Kia EV 6 vehicles from 2022 through 2024. The affiliated Korean automakers say in government documents that a transistor in a charging control unit can be damaged and stop charging the 12-volt battery. Dealers will inspect and replace the control unit and a fuse if needed. They also will update software. Christmas TV movies are in their Taylor Swift era, with two Swift-inspired films airing this year Two of the new holiday movies coming to TV this season have a Taylor Swift connection that her fans would have no problem decoding. “Christmas in the Spotlight” debuts Saturday on Lifetime. It stars Jessica Lord as the world’s biggest pop star and Laith Wallschleger, playing a pro football player, who meet and fall in love, not unlike Swift and her boyfriend, Kansas City Chiefs tight end Travis Kelce. On Nov. 30, Hallmark will air “Holiday Touchdown: A Chiefs Love Story.” Instead of a nod to Swift, it’s an ode to family traditions and bonding, like rooting for a sports team. Hallmark’s headquarters is also in Kansas City.
Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic modalities to target cancers. Due to recent communications with the U.S. Food and Drug Administration (FDA, or the Agency) regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the Company has decided to pursue strategic options for the further development and commercialization of this product candidate. The CLOVER-WaM study was conducted in accordance with earlier FDA communications from an end of Phase 2 meeting and from a meeting in early 2024, during which the Company was informed that positive results for major response rate (MRR) as the primary endpoint could be acceptable to support accelerated approval of iopofosine I 131 as a treatment for Waldenstrom’s macroglobulinemia (WM). Based upon a recent Type-C meeting with the FDA, the Company now believes that a submission seeking accelerated approval would need to be based on the MRR data from CLOVER-WaM and enrollment in a randomized, controlled confirmatory study that is designed to generate data on progression-free survival (PFS). “While iopofosine I 131’s positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources. Importantly, partnering or divesting this program supports our commitment to providing this potentially life-saving drug to the patients who need it as quickly as possible,” stated James Caruso, president and CEO of Cellectar. “We believe iopofosine I 131 represents a compelling opportunity as it has shown strong efficacy and good tolerability based on our clinical studies. Moreover, the commercial work we conducted demonstrates iopofosine I 131’s substantial market opportunity based upon the product profile, which includes off-the-shelf global distribution, orphan pricing and existing unmet medical need.” Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131’s clinical success validates the platform’s ability to target cancers and Cellectar will leverage its experience to focus on the development of its earlier clinical programs. Specifically, Cellectar will focus on those assets it believes have the highest therapeutic potential and opportunity for value creation. As highlighted by recent acquisitions and collaborations within the radiopharmaceutical sector, precision isotopes like alpha- and Auger-emitters have emerged as the leading therapeutics of interest. Consequently, the Company will now focus its resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. Cellectar expects to file Investigational New Drug applications in the first half of 2025 for both CLR-121225 and CLR-121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers. Both programs have demonstrated robust in vivo activity, tolerability, excellent targeting and uptake in preclinical solid tumor models. The Company believes this approach will provide an expedited timeframe to achieve safety and proof-of-concept data in patients. The Company’s strategic reprioritization will impact all departments and result in an immediate reduction in headcount of approximately 60%, which should be complete by the end of the fourth quarter 2024. The Company anticipates that the implementation of the restructuring will extend its cash runway into the third quarter of 2025. “We are being methodical in our efforts to reorganize the company with the goal of conserving cash while maintaining the flexibility to execute immediate priorities and build for long-term growth and value creation. This reorganization is difficult but necessary for the future growth potential of Cellectar,” said Mr. Caruso. “I want to extend my deepest gratitude to our departing employees for their significant contributions to our work and their dedication to making a difference in the lives of patients.” About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset, iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer, CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 is under evaluation in Phase 2b studies for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, alongside the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 Orphan Drug and Fast Track Designations for various cancer indications. New data from the CLOVER-WaM Phase 2 clinical trial were recently presented in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024). For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook. Forward-Looking Statement Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to obtain regulatory exclusivities, the availability of priority review vouchers, our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. Contacts MEDIA: Christy Maginn Bliss Bio Health 703-297-7194 cmaginn@blissbiohealth.com INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 annemarie.fields@precisionaq.comUnai Emery felt his Aston Villa side restored confidence by returning to winning ways with a 3-1 victory over Brentford in the Premier League. Morgan Rogers’ fourth goal of the season, an Ollie Watkins penalty and Matty Cash’s finish put Villa 3-0 up after 34 minutes. Mikkel Damsgaard pulled one back for Brentford in the second half but the damage had been done as Villa ended their eight-match winless run in all competitions. Emery was relieved to end the unwanted streak but quickly turned his attention to the next fixture against Southampton on Saturday. “We broke a spell of bad results we were having,” the Villa boss said. “We started the first five or 10 minutes not in control of the game but then progressively we controlled. “Today we achieved those three points and it has given us confidence again but even like that it’s not enough. We have to keep going and think about the next match against Southampton on Saturday. “The message was try to focus on each match, try to forget the table. How we can recover confidence and feel comfortable at home. Today was a fantastic match.” Tyrone Mings returned to the starting line-up in the Premier League for the first time since August 2023. Emery admitted it has been a long road back for the 31-year-old and is pleased to have him back. He added: “Mings played in the Champions league but it’s the first time in the league for a year and three months. “I think he played fantastic – he might be tired tomorrow but will be ready for Saturday again. “It was very, very long, the injury he had. His comeback is fantastic for him and everybody, for the doctor and physio and now he’s training everyday.” Brentford fell to a sixth away defeat from seven games and have picked up only a solitary point on the road this season. They have the best home record in the league, with 19 points from seven matches, but they have the joint worst away record. Bees boss Thomas Frank is confident form will improve on the road. He said: “On numbers we can’t argue we are better at home than away, but on numbers it’s a coincidence. I think two of the seven away games have been bad. “The other games we performed well in big spells. I’m confident at the end of the season we will have some wins away from home.” Frank felt Villa should not have been given a penalty when Ethan Pinnock brought Watkins down. He added: “I want to argue the penalty. I don’t think it is (one). I think Ollie kicked back and hit Ethan, yes there is an arm on the shoulder but threshold and all that – but that’s not the reason we lost.”
No. 2 Ohio State takes control in the 2nd half and runs over No. 5 Indiana 38-158 Things to Remember About Dexter’s Childhood Before ‘Original Sin’
Mary Fowler's has been overshadowed by a serious injury to captain Alex Greenwood, with fans left devastated for the English star. Fowler and helped City defeat St Polten in the women's Champions League on Thursday night to maintain top spot in Group D. It was Fowler's second win in two games since returning to action following her decision to against Brazil and Chinese Taipei to prioritise her physical and mental health. The break appears to have done the trick, with Fowler scoring a cracking goal earlier this week in the Super League and following it up with another solid performance on Wednesday night. But her successful return was overshadowed when Greenwood went down with a horrible-looking injury against St Polten. The England defender went down in obvious pain during the first half and was clutching her left knee. She covered her face with her shirt as she was carried off the field on a stretcher. City will be hoping the injury isn't as bad as it looked, but there are fears she might have done her ACL. There was been a plague of ACL injuries to hit the women's game in recent years, with Matildas captain with one. Greenwood's injury also marred a night which saw a debut to remember for 18-year-old Lily Murphy, who only signed her first professional contract last week. The teenager was lively throughout the game and held her arms aloft in delight when she tapped in the opening goal in the 55th minute, with Kerstin Casparij also scoring her first goal for the club. The victory maintained City's perfect record in the Champions League. However Barcelona's 3-0 victory over Hammarby means Fowler's team are not yet assured of top spot in the group ahead of a trip to Catalonia next week. Hope she's back on the pitch soon 🙏 — Aabid (@theabuabid) Was absolutely heartbreaking to see her so distressed, wish the cameras would have for respect for the players and not show them in those situations. — Toni Hazell (@tonihazell) I’m praying it’s not as bad as it looked. 🤞🏻🤞🏻 — Nicole (@nrstanley01) If Alex Greenwood has torn her ACL cancel the whole of next years euros I’m so serious — Eden Morgan (@EdenVMorgan) genuinely praying that alex greenwood is okay and makes a safe and speedy recovery. such an important player for both club and country right now in such consistent form, an absolutely heartbreaking thing to see☹️ — emily (@emilykatrinah_) Wishing a super speedy recovery. Such a warrior of a player, she doesn’t go off the pitch without a real reason. That looked serious. — Jenni 🏳️🌈❤️🔥🏳️⚧️ (@Jenwah) Meanwhile, fellow Matildas players Caitlin Foord and Kyra Cooney-Cross started in Arsenal's 3-1 win at Valerenga, while Steph Catley wasn't required. Alessio Russo scored a double as the Gunners took a big step towards securing top spot in Group C. Arsenal were already guaranteed a quarter-final berth after a narrow victory at home to Juventus last month, but the three points in Norway keep alive the prospect of beating current leaders Bayern Munich to first position in the group. First-half goals by Russo and Frida Maanum put Renee Slegers' side in control before England forward Russo grabbed a second after the break. Foord was brilliant on the wing and set up a number of attacking raids, including one that resulted in Maanum's goal. Arsenal earned an eighth win in nine under interim coach Slegers ahead of Wednesday's visit of Bayern, who are one point ahead of the English club following a 4-0 triumph over Juventus.President-elect Donald Trump's pick for health secretary, Robert F. Kennedy Jr., said Thursday he believes anti-obesity drugs "have a place." The comment, given in a brief interview to CNBC off the floor of the New York Stock Exchange, was the strongest suggestion yet that, if confirmed to take over the Department Health and Human Services, Kennedy wouldn't necessarily move to block access to a class of drugs that he's sharply criticized in the past but that doctors are hailing as a powerful tool in the obesity epidemic. When asked how he felt by drugs that mimic the actions of the GLP-1 hormone, Kennedy said "the first line of response should be lifestyle, it should be eating well, making sure that you don't get obese, and that those GLP drugs have a place." MORE: Elon Musk shows support for weight loss drugs despite RFK Jr.'s criticism Kennedy's aside comes one day after Trump adviser Elon Musk said he believes "nothing would do more to improve the health, lifespan and quality of life for Americans than making GLP inhibitors super low cost to the public." The seeming endorsement of medications such as Ozempic, Wegovy, Mounjaro and Zepbound from two people who have Trump's ear is likely to be a relief for the pharmaceutical industry following Kennedy's sharp questioning of America's reliance on weight-loss medications. Previously, Kennedy has said that if America paid more for quality food, it would solve the obesity crisis "overnight" -- a statement obesity experts criticized as overly simplistic. MORE: Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: Study Still in question is how the incoming administration plans to handle coverage of the drugs through Medicare and Medicaid and any regulation of the private insurance industry. The Biden administration has called for Medicare and Medicaid to expand coverage of weight-loss drugs for people struggling with obesity, not just as a treatment for diabetes. But because that rule won't kick in until 2026, it'll be up to the incoming administration to enact. Covering GLP-1 drugs under federal health insurance programs would come at a significant cost to the country. The Congressional Budget Office estimates that expanding coverage of anti-obesity drugs in Medicare alone would increase federal spending by about $35 billion from 2026 to 2034. Calley Means, a top adviser to Kennedy, has criticized the Biden proposal's embrace of weight-loss drugs instead of pushing lifestyle changes and suggested that the incoming administration should work on "benefit flexibility where patients can work with their doctors on the best solution to reverse obesity for them," including "lifestyle coaching, food interventions, or, in some cases, drugs." Means also said the government should ensure the price mirrors European costs. "The problem isn't that Ozempic exists," Means tweeted on Thursday. "It is the fact that this Danish company has been able to pay US regulators, media, and lawmakers to force this drug down our throats as the only option." In the CNBC interview on Thursday, Kennedy also reiterated his stance that he doesn't oppose all vaccines. While Kennedy has said he's not opposed to all vaccines, he has falsely claimed that childhood vaccines cause autism, despite the retraction of the fraudulent study that originally suggested this link, and numerous subsequent high-quality studies disproving this theory. In a Time magazine interview, Trump said the issue of vaccine safety still warrants a "big discussion" and that he would be open to restricting some vaccines if Kennedy found them "dangerous." Kennedy has said he is "fully vaccinated," except against COVID-19.
